506 related articles for article (PubMed ID: 33033851)
1. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.
Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC
Cancer Immunol Immunother; 2021 Apr; 70(4):1127-1142. PubMed ID: 33033851
[TBL] [Abstract][Full Text] [Related]
2. Patients with gastrointestinal irritability after TGN1412-induced cytokine storm displayed selective expansion of gut-homing αβ and γδT cells.
McCarthy NE; Stagg AJ; Price CL; Mann ER; Gellatly NL; Al-Hassi HO; Knight SC; Panoskaltsis N
Cancer Immunol Immunother; 2021 Apr; 70(4):1143-1153. PubMed ID: 33048222
[TBL] [Abstract][Full Text] [Related]
3. Myelopoiesis of acute inflammation: lessons from TGN1412-induced cytokine storm.
Panoskaltsis N; McCarthy NE; Knight SC
Cancer Immunol Immunother; 2021 Apr; 70(4):1155-1160. PubMed ID: 32862238
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
6. Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.
Dudek S; Weißmüller S; Anzaghe M; Miller L; Sterr S; Hoffmann K; Hengel H; Waibler Z
Eur J Immunol; 2019 Jul; 49(7):1117-1126. PubMed ID: 31002172
[TBL] [Abstract][Full Text] [Related]
7. After TGN1412: recent developments in cytokine release assays.
Stebbings R; Eastwood D; Poole S; Thorpe R
J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
[TBL] [Abstract][Full Text] [Related]
8. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
[TBL] [Abstract][Full Text] [Related]
9. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
Hünig T
FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
[TBL] [Abstract][Full Text] [Related]
10. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
Sandilands GP; Wilson M; Huser C; Jolly L; Sands WA; McSharry C
Clin Exp Immunol; 2010 Dec; 162(3):516-27. PubMed ID: 20964641
[TBL] [Abstract][Full Text] [Related]
11. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
[TBL] [Abstract][Full Text] [Related]
12. CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade.
Sundqvist KG
Front Immunol; 2021; 12():670864. PubMed ID: 33968078
[No Abstract] [Full Text] [Related]
13. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
[TBL] [Abstract][Full Text] [Related]
14. The calm after the cytokine storm: lessons from the TGN1412 trial.
St Clair EW
J Clin Invest; 2008 Apr; 118(4):1344-7. PubMed ID: 18357347
[TBL] [Abstract][Full Text] [Related]
15. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
[TBL] [Abstract][Full Text] [Related]
16. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
[TBL] [Abstract][Full Text] [Related]
17. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
19. T cell immunobiology and cytokine storm of COVID-19.
Luo XH; Zhu Y; Mao J; Du RC
Scand J Immunol; 2021 Mar; 93(3):e12989. PubMed ID: 33113222
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.
Hussain K; Hargreaves CE; Roghanian A; Oldham RJ; Chan HT; Mockridge CI; Chowdhury F; Frendéus B; Harper KS; Strefford JC; Cragg MS; Glennie MJ; Williams AP; French RR
Blood; 2015 Jan; 125(1):102-10. PubMed ID: 25395427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
